Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.15Last Year’s EPS
-0.81Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -1.81%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call provided an optimistic outlook with significant clinical advancements and a strong financial position, despite increased R&D expenses and net loss.Company Guidance
During the Q1 2025 earnings call for Revolution Medicines, multiple metrics and strategic updates were shared regarding their ongoing and future clinical trials. The company reported a cash reserve of $2.1 billion, expected to fund operations until the second half of 2027. R&D expenses rose to $205.7 million from $118 million the previous year, mainly due to increased clinical trial and manufacturing activities, particularly for the daraxonrasib program, now in two Phase 3 trials. G&A expenses increased to $35 million from $22.8 million, driven by personnel and commercial preparation costs. The net loss for the quarter expanded to $213.4 million from $116 million in Q1 2024. The company reiterated its full-year 2025 GAAP net loss projection between $840 million and $900 million, including non-cash stock-based compensation of $115 million to $130 million. Revolution Medicines continues to advance its portfolio of RAS(ON) inhibitors, with Phase 3 trials planned for daraxonrasib in first-line metastatic pancreatic cancer and non-small cell lung cancer in 2025, aiming to transform treatment across RAS mutant cancer types, with pivotal combination trials expected to initiate in 2026.Strong Financial Position
Ended the first quarter of 2025 with $2.1 billion in cash and investments, projected to fund operations into the second half of 2027.
Promising Clinical Developments
Daraxonrasib, elironrasib, and zoldonrasib showed promising anti-tumor activity in non-small cell lung cancer and pancreatic cancer, with plans to initiate more Phase 3 trials.
Global Expansion for Daraxonrasib
The RASolute 302 trial in pancreatic cancer is enrolling patients in the U.S., EU, and Japan, with expected data readout in 2026.
Positive Phase 3 Enrollment Progress
Phase 3 trials for daraxonrasib in both previously treated pancreatic and non-small cell lung cancers are progressing well.
RVMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RVMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $37.66 | $41.91 | +11.29% |
Feb 26, 2025 | $40.50 | $39.08 | -3.51% |
Nov 06, 2024 | $59.42 | $59.10 | -0.54% |
Aug 07, 2024 | $42.27 | $41.98 | -0.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Revolution Medicines (RVMD) report earnings?
Revolution Medicines (RVMD) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Revolution Medicines (RVMD) earnings time?
Revolution Medicines (RVMD) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RVMD EPS forecast?
RVMD EPS forecast for the fiscal quarter 2025 (Q2) is -1.15.
